Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
3
|
| pubmed:dateCreated |
1997-3-6
|
| pubmed:abstractText |
We investigated both the effect and the mechanism of oral (p.o.) administration of PSK, a protein-bound polysaccharide derived from Basidiomycetes, on the anti-tumor T-cell response in gut-associated lymphoid tissue (GALT). The p.o. administration of PSK significantly suppressed the growth of colon 26 carcinoma (C-26) inoculated into the subserosal space of the cecum (i.c.), and augmented the tumor-neutralizing activity of the draining mesenteric lymph node (LN) cells. PSK treatment also significantly decreased the levels of immunosuppressive factors such as plasma transforming growth factor (TGF)-beta in the i.c. C-26-inoculated mice. We also evaluated the improving effect of PSK on the anti-tumor T-cell response in GALT by utilizing B7-transfected P815 mastocytoma (B7/P815). The PSK treatment promoted the rejection of i.c.-inoculated B7/P815 and restored the CD4+ T-cell-dependent proliferative response of the draining mesenteric LN cells against in vitro restimulation. Furthermore, the treatment also decreased the TGF-beta production but increased the IFN-gamma production of these cells. The p.o. administration of PSK, however, showed no effect in the CD8+ T-cell-dependent cytolytic activity of the draining mesenteric LN cells after in vitro restimulation. Overall, these results indicate that the p.o. administration of PSK can improve the impaired anti-tumor CD4+ T-cell response in GALT, mainly through a suppression of TGF-beta production and a restoration of IFN-gamma production.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antibiotics, Antineoplastic,
http://linkedlifedata.com/resource/pubmed/chemical/Immunologic Factors,
http://linkedlifedata.com/resource/pubmed/chemical/Interferon-gamma,
http://linkedlifedata.com/resource/pubmed/chemical/Proteoglycans,
http://linkedlifedata.com/resource/pubmed/chemical/Transforming Growth Factor beta,
http://linkedlifedata.com/resource/pubmed/chemical/krestin
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Jan
|
| pubmed:issn |
0020-7136
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:day |
27
|
| pubmed:volume |
70
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
362-72
|
| pubmed:dateRevised |
2008-11-21
|
| pubmed:meshHeading |
pubmed-meshheading:9033641-Administration, Oral,
pubmed-meshheading:9033641-Animals,
pubmed-meshheading:9033641-Antibiotics, Antineoplastic,
pubmed-meshheading:9033641-CD4-Positive T-Lymphocytes,
pubmed-meshheading:9033641-CD8-Positive T-Lymphocytes,
pubmed-meshheading:9033641-Colonic Neoplasms,
pubmed-meshheading:9033641-Female,
pubmed-meshheading:9033641-Humans,
pubmed-meshheading:9033641-Immunologic Factors,
pubmed-meshheading:9033641-Immunosuppression,
pubmed-meshheading:9033641-Interferon-gamma,
pubmed-meshheading:9033641-Lymph Nodes,
pubmed-meshheading:9033641-Mesentery,
pubmed-meshheading:9033641-Mice,
pubmed-meshheading:9033641-Mice, Inbred BALB C,
pubmed-meshheading:9033641-Neoplasm Transplantation,
pubmed-meshheading:9033641-Proteoglycans,
pubmed-meshheading:9033641-Specific Pathogen-Free Organisms,
pubmed-meshheading:9033641-Transforming Growth Factor beta
|
| pubmed:year |
1997
|
| pubmed:articleTitle |
Oral administration of PSK can improve the impaired anti-tumor CD4+ T-cell response in gut-associated lymphoid tissue (GALT) of specific-pathogen-free mice.
|
| pubmed:affiliation |
Department of Virology, Kyushu University, Fukuoka, Japan. harada@bioreg.kyushu-u.ac.jo
|
| pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|